• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Astrocytoma - Pipeline Review, Q2 2011 - Product Image

Astrocytoma - Pipeline Review, Q2 2011

  • ID: 1801417
  • April 2011
  • 143 pages
  • Global Markets Direct

Astrocytoma - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Astrocytoma - Pipeline Review, Q2 2011', provides an overview of the Astrocytoma therapeutic pipeline. This report provides information on the therapeutic development for Astrocytoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Astrocytoma. 'Astrocytoma - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Astrocytoma.
- A review of the Astrocytoma products under development by companies and universities/research institutes based on information derived from company and READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Astrocytoma Overview
Therapeutics Development
An Overview of Pipeline Products for Astrocytoma
Astrocytoma Therapeutics under Development by Companies
Astrocytoma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Astrocytoma Therapeutics - Products under Development by Companies
Astrocytoma Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Astrocytoma Therapeutics Development
Bristol-Myers Squibb Company
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Sanofi-Aventis
AstraZeneca PLC
Eli Lilly and Company
GlaxoSmithKline plc
Merck & Co., Inc.
Lentigen Corporation
Sangamo BioSciences, Inc.
Takeda Pharmaceutical Company Limited
NeoPharm, Inc.
YM BioSciences Inc.
MediGene AG
Ark Therapeutics Group plc
Neurocrine Biosciences, Inc.
Novartis AG
Astellas Pharma Inc.
Nippon Shinyaku Co., Ltd.
Pfizer Inc.
Teva Pharmaceutical Industries Limited
Genmab A/S
Exelixis, Inc.
Celgene Corporation
Geron Corporation
Merck KGaA
Access Pharmaceuticals, Inc.
EntreMed, Inc.
GW Pharmaceuticals plc
Celldex Therapeutics, Inc.
ImmunoCellular Therapeutics, Ltd.
Lixte Biotechnology Holdings, Inc.
Northwest Biotherapeutics, Inc.
Novogen Limited
Peregrine Pharmaceuticals, Inc.
Telik, Inc.
Transcept Pharmaceuticals, Inc.
Pharmacyclics, Inc.
PhytoMedical Technologies, Inc.
Transgene SA
Sareum Holdings plc
Bradmer Pharmaceuticals Inc.
Proximagen Neuroscience plc.
Protox Therapeutics Inc.
Rexahn Pharmaceuticals, Inc.
Debiopharm Group
Antisense Pharma GmbH
Ambit Biosciences Corporation
Immupharma Plc
Vaxon Biotech
Advantagene, Inc.
Apogenix GmbH
Indena S.p.A.
Unibioscreen S.A.
Pivotal BioSciences, Inc.
Reata Pharmaceuticals, Inc.
Vascular Biogenics Ltd.
BioCancell Therapeutics, Inc.
Axelar AB
TransMolecular, Inc.
Siena Biotech S.p.A.
Expression Genetics, Inc.
ChemoCentryx, Inc.
TVAX Biomedical, LLC
Hy BioPharma Inc.
ZGene A/S
Nexgenix Pharmaceuticals, LLC
Archer Biosciences, Inc
TAU Therapeutics, LLC
Tocagen Inc
CytomX, LLC.
Astrocytoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Enzastaurin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Impetreve - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Avastin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cilengitide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cintredekin Besudotox - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Trabedersen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Xcytrin- - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cerepro - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cediranib + Lomustine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chloroquine for Glioblastoma Multiforme (National Institute of Neurology and Neurosurgery, Mexico) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SU-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cilengitide + Temozolomide + Radiotherapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gleevec + Hydroxyurea - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Avastin + Temozolomide + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temozolomide + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lomustine + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carmustine + O6-Benzylguanine + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carmustine + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temozolomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temozolomide + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temozolomide + Lomustine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temodar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Radiation Therapy + Procarbazine + ACNU - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Radiation Therapy + ACNU - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Thioguanine + Procarbazine + Lomustine + Vincristine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
leflunomide + procarbazine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
radiation therapy + carmustine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temozolomide + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Procarbazine + Lomustine + Vincristine + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temozolomide + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Astrocytoma Therapeutics – Drug Profile Updates
Astrocytoma Therapeutics - Discontinued Products
Astrocytoma - Featured News
Apr 08, 2011: Polaris Reports Transcriptional Silencing Of ASS1 Suggests Potential Use Of ADI-PEG 20 To Treat AML, Glioblastoma And Bladder Cancer
Apr 06, 2011: VBL Therapeutics Presents Two Studies On VB-111 At 102nd Annual AACR Meeting
Feb 03, 2011: Myrexis Announces Azixa Clinical Data Publications
Feb 02, 2011: ImmunoCellular Therapeutics Initiates Enrollment In Phase II Trial of ICT-107
Jan 31, 2011: VBL Initiates Phase I/II Clinical Trial Of VB-111 For Glioblastoma Multiforme
Jan 24, 2011: Apogenix Provides Update On Ongoing Phase II Clinical Trial Of APG101 To Treat Glioblastoma
Jan 24, 2011: Northwest Biotherapeutics Resuming Enrollment In 240-Patient Clinical Trial Of DCVax For Brain Cancer
Jan 04, 2011: ImmunoCellular Receives FDA Approval To Commence ICT-107 Phase II Trial In Glioblastoma Multiforme
Dec 26, 2010: BioCancell Announces Success In PreClinical Trial Of BC-821 In Glioblastoma
Dec 20, 2010: Peregrine Completes Phase II Cotara Brain Cancer Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Astrocytoma, Q2 2011
Products under Development for Astrocytoma – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Early Clinical Stage Development, Q2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Products under Development by Companies, Q2 2011
Products under Development by Companies, Q2 2011
Products under Development by Companies, Q2 2011
Products under Development by Companies, Q2 2011
Products under Development by Companies, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Bristol-Myers Squibb Company, 2011
Boehringer Ingelheim GmbH, 2011
F. Hoffmann-La Roche Ltd., 2011
Sanofi-Aventis, 2011
AstraZeneca PLC, 2011
Eli Lilly and Company, 2011
GlaxoSmithKline plc, 2011
Merck & Co., Inc., 2011
Lentigen Corporation, 2011
Sangamo BioSciences, Inc., 2011
Takeda Pharmaceutical Company Limited, 2011
NeoPharm, Inc., 2011
YM BioSciences Inc., 2011
MediGene AG, 2011
Ark Therapeutics Group plc, 2011
Neurocrine Biosciences, Inc., 2011
Novartis AG, 2011
Astellas Pharma Inc., 2011
Nippon Shinyaku Co., Ltd., 2011
Pfizer Inc., 2011
Teva Pharmaceutical Industries Limited, 2011
Genmab A/S, 2011
Exelixis, Inc., 2011
Celgene Corporation, 2011
Geron Corporation, 2011
Merck KGaA, 2011
Access Pharmaceuticals, Inc., 2011
EntreMed, Inc., 2011
GW Pharmaceuticals plc, 2011
Celldex Therapeutics, Inc., 2011
ImmunoCellular Therapeutics, Ltd., 2011
Lixte Biotechnology Holdings, Inc., 2011
Northwest Biotherapeutics, Inc., 2011
Novogen Limited, 2011
Peregrine Pharmaceuticals, Inc., 2011
Telik, Inc., 2011
Transcept Pharmaceuticals, Inc., 2011
Pharmacyclics, Inc., 2011
PhytoMedical Technologies, Inc., 2011
Transgene SA, 2011
Sareum Holdings plc, 2011
Bradmer Pharmaceuticals Inc., 2011
Proximagen Neuroscience plc., 2011
Protox Therapeutics Inc., 2011
Rexahn Pharmaceuticals, Inc., 2011
Debiopharm Group, 2011
Antisense Pharma GmbH, 2011
Ambit Biosciences Corporation, 2011
Immupharma Plc, 2011
Vaxon Biotech, 2011
Advantagene, Inc., 2011
Apogenix GmbH, 2011
Indena S.p.A., 2011
Unibioscreen S.A., 2011
Pivotal BioSciences, Inc., 2011
Reata Pharmaceuticals, Inc., 2011
Vascular Biogenics Ltd., 2011
BioCancell Therapeutics, Inc., 2011
Axelar AB, 2011
TransMolecular, Inc., 2011
Siena Biotech S.p.A., 2011
Expression Genetics, Inc., 2011
ChemoCentryx, Inc., 2011
TVAX Biomedical, LLC, 2011
Hy BioPharma Inc., 2011
ZGene A/S, 2011
Nexgenix Pharmaceuticals, LLC, 2011
Archer Biosciences, Inc, 2011
TAU Therapeutics, LLC, 2011
Tocagen Inc, 2011
CytomX, LLC., 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Astrocytoma Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Astrocytoma, Q2 2011
Products under Development for Astrocytoma – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Late Stage Products, Q2 2011
Mid Clinical Stage Products, Q2 2011
Early Clinical Stage Products, Q2 2011
Discovery and Pre-Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos